Each tablet contains Atorvastatin 5 mg, 10 mg, 20 mg, 40 mg, or 80 mg.

Avas Tablets contain Atorvastatin, a potent HMG-CoA reductase inhibitor (statin) indicated for the management of hypercholesterolemia and mixed dyslipidemia. It effectively lowers LDL cholesterol, total cholesterol, and triglycerides, while modestly increasing HDL cholesterol, thereby reducing the risk of atherosclerotic cardiovascular disease. Avas Tablets are recommended as an adjunct to dietary modification, regular exercise, and other lifestyle measures for optimal lipid control.

Avas Tablets are indicated as an adjunct to diet for reducing elevated total cholesterol and triglyceride levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Type IIa and Type IIb).

Atorvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme involved in cholesterol biosynthesis. By inhibiting the conversion of HMG-CoA to mevalonate, it reduces hepatic cholesterol synthesis and increases the expression of LDL receptors, thereby enhancing the clearance of circulating low-density lipoprotein cholesterol (LDL-C). Cholesterol and triglycerides circulate within HDL, IDL, LDL, and VLDL lipoprotein fractions, and Atorvastatin effectively improves the lipid profile by reducing LDL-C, total cholesterol, and triglycerides while modestly increasing HDL-C.

Atorvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme involved in cholesterol biosynthesis. By inhibiting the conversion of HMG-CoA to mevalonate, it reduces hepatic cholesterol synthesis and increases the expression of LDL receptors, thereby enhancing the clearance of circulating low-density lipoprotein cholesterol (LDL-C). Cholesterol and triglycerides circulate within HDL, IDL, LDL, and VLDL lipoprotein fractions, and Atorvastatin effectively improves the lipid profile by reducing LDL-C, total cholesterol, and triglycerides while modestly increasing HDL-C.

Avas Tablets are contraindicated in patients with active liver disease, known hypersensitivity to Atorvastatin or any component of the formulation, and in pregnant or breastfeeding women.